Alvesco is an asthma management drug owned by Covis. This drug, which was first authorized for market use on 10th January, 2008, contains the active ingredient ciclesonide and is available in aerosol, metered; inhalation dosage forms. Alvesco holds a total of 1 patent, all of which are currently in effect.
The generic version of Alvesco is expected to become available after 1st February, 2028. This release date corresponds with the expiration of the drug's last patent held under the title 'Use of ciclesonide for the treatment of respiratory diseases', suggesting that the availability of Alvesco generics hinges largely on this patent.
Alvesco is used as a maintenance treatment for asthma, serving as prophylactic therapy in adults and adolescents aged 12 years and up. The patent for Alvesco also covers the method for treating a respiratory disease in a child.
Alvesco possesses a single patent titled 'Use of ciclesonide for the treatment of respiratory diseases' that expires on 1st February, 2028. The release of Alvesco generic is therefore anticipated to occur after this date. Below are the details of the patent: